Morgan Stanley Has Lowered Expectations for Trevi Therapeutics (NASDAQ:TRVI) Stock Price

Trevi Therapeutics (NASDAQ:TRVI) had its price objective lowered by equities researchers at Morgan Stanley from $19.00 to $18.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s price objective points to a potential upside of 68.22% from the company’s current price.

Several other research analysts also recently weighed in on TRVI. Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Wednesday, January 21st. Oppenheimer restated an “outperform” rating on shares of Trevi Therapeutics in a research note on Monday, March 9th. D. Boral Capital reaffirmed a “buy” rating and set a $19.00 price objective on shares of Trevi Therapeutics in a report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a research report on Monday, March 9th. Finally, Needham & Company LLC lifted their target price on shares of Trevi Therapeutics from $22.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Trevi Therapeutics currently has an average rating of “Buy” and an average price target of $21.60.

Trevi Therapeutics Trading Up 0.1%

Trevi Therapeutics stock opened at $10.70 on Wednesday. The business’s 50 day simple moving average is $11.14 and its 200 day simple moving average is $10.93. Trevi Therapeutics has a 12 month low of $4.85 and a 12 month high of $14.39. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -33.44 and a beta of 0.94.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04. As a group, equities research analysts forecast that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Alliancebernstein L.P. lifted its position in Trevi Therapeutics by 19,064.5% during the second quarter. Alliancebernstein L.P. now owns 4,281,355 shares of the company’s stock valued at $23,419,000 after purchasing an additional 4,259,015 shares during the last quarter. Rubric Capital Management LP increased its holdings in shares of Trevi Therapeutics by 88.0% in the 2nd quarter. Rubric Capital Management LP now owns 8,531,860 shares of the company’s stock worth $46,669,000 after buying an additional 3,993,325 shares during the last quarter. Viking Global Investors LP increased its holdings in shares of Trevi Therapeutics by 232.4% in the 3rd quarter. Viking Global Investors LP now owns 5,128,875 shares of the company’s stock worth $46,929,000 after buying an additional 3,585,875 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Trevi Therapeutics by 1,792.0% during the 3rd quarter. Wellington Management Group LLP now owns 3,253,888 shares of the company’s stock valued at $29,773,000 after buying an additional 3,081,906 shares in the last quarter. Finally, Marshall Wace LLP raised its position in shares of Trevi Therapeutics by 95.4% during the 3rd quarter. Marshall Wace LLP now owns 4,841,751 shares of the company’s stock valued at $44,302,000 after buying an additional 2,363,835 shares in the last quarter. Hedge funds and other institutional investors own 95.76% of the company’s stock.

More Trevi Therapeutics News

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Company says it achieved FDA alignment and plans two pivotal Phase III trials for IPF‑related chronic cough — a major pipeline and regulatory de‑risking milestone that can drive long‑term value if trials and endpoints are favorable. Article Title
• Positive Sentiment: Q4 2025 results topped expectations — EPS of ($0.06) vs. consensus ~($0.0966). The beat and management commentary from the earnings call support near‑term credibility on execution. Earnings Transcript
• Positive Sentiment: Broker support remains strong: Needham raised its target to $24 (Buy) and HC Wainwright reiterated a Buy with a $21 target and updated EPS forecasts — analyst backing increases visibility for upside expectations. Broker Note HC Wainwright Details
• Positive Sentiment: D. Boral Capital reaffirmed a Buy and $19 target, adding to the cluster of buy ratings—positive for investor sentiment and analyst coverage breadth. Article Title
• Neutral Sentiment: Morgan Stanley lowered its price target from $19 to $18 but kept an Overweight rating — still positive sentimentually, but the cut trims some near‑term upside expectations. Article Title
• Negative Sentiment: JonesTrading trimmed its target from $25 to $24 (remains a Buy) — a modest downward adjustment in analyst upside that slightly cools the market’s price‑target momentum. Article Title

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.